Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
KAIST In Situ CAR-Macrophage Therapy
/in Immunotherapy, Preclinical Research/by MaxThe KAIST team has introduced a highly innovative form of cancer immunotherapy that turns the body’s own macrophages into potent, targeted cancer killers directly inside solid tumours. Instead of the classic, laborious route of extracting immune cells from a patient, engineering them in a lab, expanding them, and reinfusing them, this approach reprograms macrophages already […]
From T Cells to B Cells: The Next Generation of Personalized Cancer Vaccines
/in Immunotherapy, Preclinical Research/by MaxA research team at the Korea Advanced Institute of Science and Technology (KAIST) has developed a new artificial intelligence model that could change how personalized cancer vaccines are designed. For decades, most cancer vaccine strategies have focused on training the immune system’s T cells to attack tumors quickly and directly, which can shrink tumors but […]
HRS-4357, a Novel PSMA-targeted Radiologand Therapy Phase 3 Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxHRS-4357, a novel PSMA-targeted radiopharmaceutical, is poised to enter a landmark Phase III clinical trial targeting metastatic castration-resistant prostate cancer (mCRPC). The trial, received approval from China’s National Medical Products Administration on December 23, 2025, and plans to enroll 370 patients across multiple centers in China. This randomized, open-label, controlled study will directly compare HRS-4357 […]
Dapagliflozin and Next-Generation Hormonal Agents: Targeting Metabolic Resistance in Metastatic Castrate-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxA new phase 2 clinical trial is now underway to test whether adding dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, to next-generation hormonal agents (darolutamide, abiraterone, apalutamide, enzalutamide) can extend survival in metastatic castrate-resistant prostate cancer. The rationale rests on a fundamental paradox in prostate cancer biology: while early tumors rely on oxidative metabolism and androgen signaling, […]
CRISPR Epigenetic Editing: Safely Reactivating Genes for Sickle Cell and Cancer’s Future
/in CRISPR, Preclinical Research/by MaxA new form of CRISPR technology developed by researchers at the University of New South Wales (UNSW Sydney) and St Jude Children’s Research Hospital promises a safer path for treating genetic diseases by controlling genes without cutting DNA strands. Published in Nature Communications, the study demonstrates epigenetic editing that removes methyl groups (small chemical clusters […]
Weizmann Institute Identifies Immunotherapy Targets in Drug-Resistant Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxResearchers from Israel’s Weizmann Institute of Science have unveiled a promising immunotherapy strategy that targets drug-resistant cancers by exploiting the very genetic mutations responsible for treatment failure. The approach centers on a computational tool called SpotNeoMet, which scans large patient datasets to identify recurrent resistance mutations that generate neo-antigens, unique protein fragments displayed exclusively […]
Immunotherapy’s Hidden Power: Reprogramming Cancer Back to Normal
/in Immunotherapy, Preclinical Research/by MaxIn a previous article, cancer reversion was introduced as the idea that malignant cells can be pushed back toward a more normal, less aggressive state instead of simply being destroyed. That earlier discussion focused mainly on epigenetic plasticity, differentiation therapy, and microenvironmental modulation as ways to coax cancer cells into behaving more like healthy tissue. […]
Phase 1 Trial of Allogeneic CAR-NK Therapy for Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxA new clinical trial is exploring allogeneic CAR-NK cell therapy targeting PSMA for patients with metastatic castration-resistant prostate cancer, or mCRPC. This exploratory study (not yet recruiting as of late 2025), aims to assess the safety profile alongside early signs of efficacy in men whose disease has progressed despite hormone suppression and other therapies. Unlike […]